ata-rai-decision

name

ata-rai-decision

description

Decides whether radioactive iodine (RAI) remnant ablation or adjuvant therapy is indicated after thyroidectomy for differentiated thyroid cancer, using ATA risk tier and specific pathologic features. Use when a clinician asks "does this DTC patient need RAI", "should I give radioiodine after thyroidectomy", "is RAI indicated for low risk thyroid cancer", "RAI for intermediate risk DTC", "radioactive iodine dosing for thyroid cancer", "RAI for lymph node metastases", or any question about post-surgical RAI decision-making in PTC or FTC. Source: 2015 ATA Guidelines, Haugen et al., Thyroid 2016;26(1).

ATA RAI Remnant Ablation / Adjuvant Therapy Decision Tool

Source: 2015 ATA Management Guidelines — Recommendations 51–55 and Table 14.
Haugen et al. Thyroid 2016;26(1). DOI: 10.1089/thy.2015.0020

---

PREREQUISITE

Before making a RAI decision:

1. Assign the ATA Initial Risk Tier (Low / Intermediate / High) → use the ATA DTC Risk Stratification skill
2. Confirm surgery: near-total or total thyroidectomy (RAI decision is only relevant after total/near-total thyroidectomy)
3. Confirm no contraindications: pregnancy, lactation, iodine overload (recent CT contrast)

---

STEP 1 — Understand the Three Indications for RAI

RAI Goal	Definition	When Used
Remnant ablation	Destroy residual normal thyroid tissue to improve Tg monitoring sensitivity	Low–intermediate risk with no known residual disease
Adjuvant therapy	Treat likely but unproven microscopic residual disease	Intermediate risk with high-risk pathologic features
Treatment	Known residual or metastatic disease (structural/functional)	High risk, incomplete resection, distant mets

---

STEP 2 — Apply the Risk-Stratified Decision Framework

❌ ATA LOW Risk — RAI NOT Routinely Recommended

Applies to:

• Unifocal PTC ≤1 cm (T1a) — intrathyroidal, no ETE, no LN involvement
• Intrathyroidal PTC T1b–T2 (1–4 cm), N0, no aggressive histology, no vascular invasion
• Intrathyroidal FTC with capsular invasion only or minimal vascular invasion (≤3 foci)
• Intrathyroidal multifocal PTMC (all foci <1 cm) without other risk factors

Rationale: RAI remnant ablation has not been shown to reduce recurrence or mortality in these patients. Surveillance with Tg and neck US is sufficient.

Exception — consider RAI even in Low Risk if:

• Aggressive histologic subtype (tall cell, hobnail, columnar)
• Vascular invasion present
• Patient/clinician preference for complete ablation to facilitate surveillance

---

🔄 ATA LOW–INTERMEDIATE Risk (T3 N0 or pN1a) — CONSIDER RAI

Applies to:

• Microscopic ETE (pT3a) into perithyroidal soft tissue, N0
• pN1a (central neck nodes positive) — ≤5 nodes, all <3 cm
• T1–T2 with 1–4 positive central nodes <0.2 cm (low-volume)

Decision: Individualise based on:

• Number and size of positive nodes
• Presence of vascular invasion
• Aggressive histologic features
• Patient age and comorbidities
• Post-surgical Tg level

→ If nodes are ≤5 micrometastases all <0.2 cm → may not require RAI
→ If >5 positive nodes or any node >0.2 cm but <3 cm → RAI generally favored

---

✅ ATA INTERMEDIATE Risk (pN1a or pN1b, aggressive features) — RAI GENERALLY RECOMMENDED

Applies to:

• Microscopic ETE with RAI-avid neck uptake on first scan
• Aggressive histologic subtype
• PTC with vascular invasion
• pN1 (central or lateral) with >5 nodes, all <3 cm
• Multifocal PTMC with ETE + BRAF mutation

Rationale: Adjuvant RAI reduces recurrence risk in this group; evidence supports benefit even without distant metastases.

---

✅✅ ATA HIGH Risk — RAI ROUTINELY RECOMMENDED

Applies to:

• Gross extrathyroidal extension (macroscopic pT4)
• Incomplete surgical resection (R1 or R2)
• Distant metastases (M1)
• Postoperative Tg suggesting distant disease
• pN1 with any single node ≥3 cm
• FTC with extensive vascular invasion (≥4 foci)

Rationale: RAI is a primary therapeutic agent. Dosing should be tailored to disease burden.

---

STEP 3 — RAI Administration Practicalities

Preparation

• Thyroid hormone withdrawal (preferred for high-risk and treatment doses): stop levothyroxine 3–4 weeks before; switch to T3 for 2 weeks, then stop T3 2 weeks before RAI
• Recombinant human TSH (rhTSH / Thyrogen): Acceptable alternative for remnant ablation (2 IM injections on Days 1 and 2; RAI on Day 3) — avoids hypothyroid morbidity; equivalent efficacy for ablation in low–intermediate risk
• Low-iodine diet: 1–2 weeks before RAI (restrict iodine intake to <50 mcg/day)
• Hold iodine-containing agents: Recent IV contrast → delay RAI 6–8 weeks; amiodarone → prolonged delay

Administered Activity

Indication	Typical Activity
Remnant ablation (low risk, limited remnant)	1.1 GBq (30 mCi) — equivalent to high-dose empirically
Remnant ablation (intermediate risk)	3.7 GBq (100 mCi)
Known residual disease / high-risk adjuvant	3.7–7.4 GBq (100–200 mCi)
Distant metastases (lung/bone)	5.5–7.4 GBq (150–200 mCi); dosimetry in selected cases

Note: 30 mCi has been shown equivalent to 100 mCi for remnant ablation in ESTIMABL and HiLo trials — use lower dose for remnant ablation in low-risk patients to minimise adverse effects.

---

STEP 4 — Post-RAI Assessment

• Post-treatment whole body scan (Rx-WBS): Perform 5–8 days after RAI administration
  • Identifies previously unknown metastatic foci
  • Positive neck uptake in the thyroid bed is expected; uptake elsewhere changes staging and management
• Serum Tg + anti-Tg antibodies: Measure at time of RAI preparation (TSH-stimulated)
  • Document baseline for future comparisons
• Follow-up: 6–12 months → thyroid neck US + TSH-stimulated or suppressed Tg → reclassify using dynamic risk stratification

---

CLINICAL GUARDRAILS

• Don't give RAI reflexively — ATA Low-risk unifocal T1a PTC has no proven benefit from RAI; avoid unnecessary treatment
• rhTSH vs. withdrawal is not equivalent for all patients — rhTSH is acceptable for remnant ablation in low–intermediate risk; for known distant disease, withdrawal may be preferred (higher TSH levels may improve RAI uptake)
• 30 mCi is enough for remnant ablation — do not dose-escalate to 100 mCi for pure remnant ablation in low–intermediate risk patients
• Iodine load is a contraindication — check for recent CT contrast before scheduling RAI; a 6–8 week delay is required after IV iodinated contrast
• Anti-Tg antibodies interfere with Tg assays — if anti-Tg is positive, Tg cannot be reliably interpreted; document and track anti-Tg trend instead
• Whole body scan for staging, not routine screening — do not perform diagnostic WBS routinely before RAI in low-risk patients; it adds radiation exposure without management benefit
• Breastfeeding must be stopped ≥6 weeks before RAI — and is contraindicated for 4–8 weeks after RAI
• Pregnancy is an absolute contraindication — confirm β-hCG negative before RAI in women of childbearing potential